Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2003

01-05-2003 | Original Article

18F-DOPA positron emission tomography for the detection of glomus tumours

Authors: Stefan Hoegerle, Nadir Ghanem, Carsten Altehoefer, Joerg Schipper, Ingo Brink, Ernst Moser, Hartmut P. H. Neumann

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2003

Login to get access

Abstract

The purpose of this study was to evaluate 18F-DOPA whole-body positron emission tomography (18F-DOPA PET) as a biochemical imaging approach for the detection of glomus tumours. 18F-DOPA PET and magnetic resonance imaging (MRI) were performed in ten consecutive patients with proven mutations of the succinate dehydrogenase subunit D (SDHD) gene predisposing to the development of glomus tumours and other paragangliomas. 18F-DOPA PET and MRI were performed according to standard protocols. Both methods were assessed under blinded conditions by two experienced specialists in nuclear medicine (PET) and diagnostic radiology (MRI). Afterwards the results were compared. A total of 15 lesions (four solitary and four multifocal tumours, the latter including 11 lesions) were detected by 18F-DOPA PET. Under blinded conditions, 18F-DOPA PET and MRI revealed full agreement in seven patients, partial agreement in two and complete disagreement in one. Eleven of the 15 presumed tumours diagnosed by 18F-DOPA PET were confirmed by MRI. The correlation of 18F-DOPA PET and MRI confirmed three further lesions previously only detected by PET. All of them were smaller than 1 cm and had the signal characteristics of lymph nodes. For one small lesion diagnosed by PET, no morphological MRI correlate could be found even retrospectively. No tumour was detected by MRI that was negative on 18F-DOPA PET. All tumours diagnosed by MRI showed a hyperintense signal on T2-weighted images and a distinct enhancement of contrast medium on T1-weighted images. The mean tumour size was 1.5±0.5 cm. 18F-DOPA PET seems to be a highly sensitive metabolic imaging procedure for the detection of glomus tumours and may have potential as a screening method for glomus tumours in patients with SDHD gene mutations.
Literature
1.
Riede UN, Saeger W. Paraganglionäres System. In: Riede UN, Schaefer HW, eds. Allgemeine und spezielle Pathologie. Stuttgart: Thieme; 1993:989–991.
2.
Tischler A, Dichter MA. Neuroendocrine neoplasm and their cells of origin. N Engl J Med 1977; 296:919–925.
3.
Gruffermann S, Gillman MW, Pasternack LR, Peterson CL, Young WG. Familial carotid body tumors: case report and epidemiologic review. Cancer 1980; 46:2116–2122.
4.
Capella C, Riva C, Cornaggia M, Chiaravalli AM, Frigerio B. Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas. Pathol Res Pract 1988; 183:176–187.
5.
Parkin JL. Familial multiple glomus tumors and pheochromocytomas. Ann Otol Rhinol Laryngol 1981; 90:60–63.
6.
Neumann HPH, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459–1466.
7.
Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531–1538.
8.
Baysal BE, Ferell RE, Willet-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paragangliomas. Science 2000; 287:848–851.
9.
Held P, Breit A. Comparison of CT and MRI methods in diagnosis of tumors of the para- and retropharyngeal space and temporal bone [in German]. Bildgebung 1994; 61:263–271.
10.
Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994; 21:561–581.
11.
van Gils APG, van der Mey AGL, Hoogma RPLM, Falke THM, Moolenar AJ, Pauwels EKJ, van Kroonenburgh MJPG. Iodine-123-metaiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region. J Nucl Med 1990; 31:1147–1155.
12.
van Gils APG, van Erkel AR, Falke THM, Pauwels EKJ. Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Eur J Nucl Med 1994; 21:239–253.
13.
Reuland P, Overkamp D, Aicher KP, Bien S, Müller Schauenburg W, Feine U. Catecholamine secreting glomus tumor detected by iodine-123-MIBG scintigraphy. J Nucl Med 1996; 37:463–465.
14.
Weissmann AF, Gonzales CE, Shapiro B, Shulkin B, Francis IR, Leach K. Multiple chemodectomas—carotid body tumor masked by salivary gland uptake on I-123 MIBG scintigraphy. Clin Nucl Med 1994; 19:527–531.
15.
Kwekkeboom DJ, van Urk H, Pauw BKH, Lamberts SWJ, Kooij PPM, Hoogma RPLM, Krenning EP. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993; 34:873–878.
16.
Schumacher A, Jonas M, Rummeny E, Schmid SH, Scheld HH, Schober O. Rezidivnachweis eines Glomus-Caroticum-Tumors mit der Somatostatin-Rezeptor-Szintigraphie. Nuklearmedizin 1996; 35:38–41.
17.
Pacak K, Eisenhofer G, Carasquillo JA, Chen CC, Li ST, Goldstein DS. [18F]Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38:6–8.
18.
Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E. Whole-body 18F-DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 2001; 220:373–380.
19.
Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E.18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28:64–71.
20.
Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HPH. Pheochromocytomas: detection with18F-DOPA whole-body PET—initial results. Radiology 2002; 222:507–512.
21.
Gimm O, Armanios M, Dziema H, Neumann HPH, Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000; 60:6822–6825.
22.
Aguiar RCT, Cox G, Pomeroy SL, Dahia PLM. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab 2001; 86:2890–2894.
23.
Luxen A, Perlmutter M, Bida GT, et al. Remote, semiautomated production of 6-[F-18]fluoro-l-dopa for human studies with PET. J Appl Radiat Isot 1990; 41:275–281.
24.
Mix M, Nitzsche EU. PISAC: a post-injection method for segmented attenuation correction in whole-body PET. J Nucl Med 1999; 40 Sl:A297P.
25.
Reinig JW, Doppmann JL, Dwyer AJ, Johnson AR, Knop RH. Adrenal masses differentiated by MR. Radiology 1986; 158:81–84.
26.
Dunnick NR. Adrenal imaging: current status. Am J Roentgenol 1990; 154:927–936.
27.
Mann W, Gilsbach J, Die chirurgische Therapie von großen Glomus jugulare Tumoren. HNO 1984; 32:249–251.
28.
Farrior J. Surgical management of glomus tumors: endocrine-active tumors of the skull base. South Med J 1988; 81:1121–1126.
29.
Jackson CG, Harris PF, Glasscock ME, Fritsch M, Dimitrov E, Johnson GD, Poe DS. Diagnosis and management of paraganglioma of the skull base. Am J Surg 1990; 159:389–393.
Metadata
Title
18F-DOPA positron emission tomography for the detection of glomus tumours
Authors
Stefan Hoegerle
Nadir Ghanem
Carsten Altehoefer
Joerg Schipper
Ingo Brink
Ernst Moser
Hartmut P. H. Neumann
Publication date
01-05-2003
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2003
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1115-3

Other articles of this Issue 5/2003

European Journal of Nuclear Medicine and Molecular Imaging 5/2003 Go to the issue

Short Communication

PET-CT: accuracy of PET and CT spatial registration of lung lesions

Molecular Imaging

Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Blue Pages

Guidelines for radioiodinated MIBG scintigraphy in children

Review Article

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

Short Communication

PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction

Blue pages

New EANM PET Learning Facility and Executive Offic